D-1396-2019 Class III Terminated
FDA drug recall D-1396-2019 was initiated by Bausch & Lomb on Jun 17, 2019 and is designated Class III. Reason for recall: Failed Stability Specifications: Out of specification for viscosity. The recall status is terminated (terminated Sep 24, 2021). Affected quantity: 170832 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 19, 2019
- Initiation Date
- Jun 17, 2019
- Termination Date
- Sep 24, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 170832 bottles
Product description
Lotemax (loteprednol etabonate ophthalmic gel 0.5%), Sterile, Rx Only, 5 g box, Bausch & Lomb, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA, NDC 24208-503-07.
Reason for recall
Failed Stability Specifications: Out of specification for viscosity.
Distribution pattern
Nationwide in the U.S.
Code information
Lot #s: 282611; 283431; 283441; 283451, Exp. 10/2019; 282971; 282981; 283611; 283621; 283631, Exp. 11/2019.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1396-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026